Rituximab in ANCA-associated disease

N Engl J Med. 2010 Jul 15;363(3):285-6. doi: 10.1056/NEJMe1004992.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / drug therapy*
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / mortality
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • B-Lymphocytes / drug effects
  • Cyclophosphamide / therapeutic use
  • Drug Therapy, Combination
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Rituximab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Glucocorticoids
  • Immunosuppressive Agents
  • Rituximab
  • Cyclophosphamide